Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 11,307

In Brief:

  • The Multiple Sclerosis Foundation estimates that more than 400,000 people in the United States and about 2.5 million people around the world have MS.
  • A new drug, Ocrelizumab, is the first known drug shown to work against the primary progressive form of MS by altering the immune system to slow damage to the brain.

Multiple sclerosis (MS) is an unpredictable and potentially disabling disease that cripples the central nervous system. It’s a widespread neurological condition that hits young adults, usually between the ages of 20 and 40, caused by an immune system disorder that mistakes a part of the brain as a hostile foreign object and attacks it. Though there are treatments available, particularly for its second state, multiple sclerosis remains incurable.

Read more

Automation in the workplace has been one of the looming existential threats to American workers for years now. And with each new study published, the fear of robots, machines, and artificial intelligence coming to take our jobs ticks higher.

But a new report from McKinsey finds that the future of work and automation isn’t quite the zero-sum game when it comes to jobs as some perceive.

Right now, 51% of job activities could be automated with “currently demonstrated” technology, the McKinsey report says. The distinction is noteworthy: McKinsey isn’t saying half of all jobs can be automated with existing technology, but rather job tasks. Many jobs involve a blend of both the mundane and the intricate. Machines are excellent at handling rote, predictable tasks like repetitive physical labor and data collection and processing, making jobs like retail, foodservice, and manufacturing —a big theme in the 2016 campaign—most affected. As 51% of all working hours, these endangered activities make up $2.7 trillion in wages.

Read more

Are you an avid supporter of aging research and a keen longevity activist?
The Biogerontology Research Foundation is offering select summer internships for talented individuals. You’d join a passionate and supportive team in researching diagnostic, prognostic, and therapeutic strategies; advising a panel of investors in developing a roadmap to promote longevity science and related technologies across the globe.

The advertised positions are 3 month internships, with the possibility of continuing afterwards. Free accommodation will be provided for in London, alongside a negotiable salary.

The Biogerontology Research Foundation is a UK based think tank dedicated to aging research and accelerating its application worldwide.

Apply to: [email protected]

Are you an avid supporter of aging research and a keen longevity activist?

The Biogerontology Research Foundation is offering select summer internships for talented individuals. You €™d join a passionate and supportive team in researching diagnostic, prognostic, and therapeutic strategies; advising a panel of investors in developing a roadmap to promote longevity science and related technologies across the globe.

Read more

More progress for tissue engineering.

Skin is one of the easier starting points for 3D bioprinting, the application of rapid prototyping technologies to the construction of living tissue. Since skin is a thin tissue, the challenging issue of producing the intricate blood vessel networks needed to supply inner cells with oxygen and nutrients can be skipped. Thin tissue sections can be supported in a suitable nutrient bath, and after transplant, patient blood vessels will grow into the new skin. Further, there is a fairly large and long-established research and development industry involved in various forms of skin regeneration. Numerous forms of prototype skin-like tissues have been created over the years, lacking many of the features of the real thing, but still useful in the treatment of, for example, burn victims. Further, skin structure is by now well understood, and considerable progress has been made in deciphering the signals and environment needed for suitable cells to self-assemble into the correct arrangements. All told, it should not be a complete surprise to see significant progress emerge in this part of the field.

Read more

Just when you thought there wasnt mushroom left for new drug discovery!

A team of Michigan State University scientists has genetically sequenced two species of poisonous mushrooms, discovering that they can theoretically produce billions of compounds through one molecular assembly line. This may open the door to efficiently tackling some lethal diseases.

The study, published in the journal BMC Genomics, reveals the DNA of two Amanita mushrooms, which are responsible for the majority of fatal mushroom poisonings.

The team will focus on the “Death Cap,” which grows all over the West Coast and Europe, and the “Destroying Angel,” native to Michigan.

Read more

Neural lace. A brain implant. Such a thing must be separate enough that if the lace is hacked nothing happens to your brain. Otherwise no deal.

In nearly the same breath as he shared updates on his plans to dig tunnels, Elon Musk also noted he’s looking to hopefully share more on his progress with developing a “neural lace” next month. That’s a technical term for direct cortical interface, and it’s something that the SpaceX and Tesla CEO takes very seriously, in case you thought he might just be having a laugh.

Musk discussed the potential of a functional neural lace at Recode’s Code conference last year, speaking earnestly about its benefits in terms of being able to help humans keep pace with advancements in AI that threaten to render us vastly inferior to complex virtual intelligences.

@BelovedRevol Maybe next month.

Read more